Literature DB >> 1546135

Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies.

R Amrein1, T W Güntert, J Dingemanse, T Lorscheid, M Stabl, W Schmid-Burgk.   

Abstract

Interactions may occur on pharmacological or pharmacokinetic grounds. Both types of interactions are discussed in relationship with the pharmacological and pharmacokinetic data of moclobemide, a reversible MAO-inhibitor. A variety of interaction studies either designed more specifically as kinetic or as dynamic studies have been performed with moclobemide. The results of these studies are presented. In view of these results as well as in view of data stemming from clinical trials it can be concluded that apart from interactions with cimetidine and pethidine, moclobemide has been shown to be devoid of relevant interactions.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1546135     DOI: 10.1007/bf02246229

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

1.  Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.

Authors:  M Da Prada; R Kettler; H H Keller; W P Burkard; D Muggli-Maniglio; W E Haefely
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

Review 2.  Monoamine oxidase inhibitors and anaesthesia. A review.

Authors:  C G Stack; P Rogers; S P Linter
Journal:  Br J Anaesth       Date:  1988-02       Impact factor: 9.166

Review 3.  Clinical pharmacology of monoamine oxidase inhibitors.

Authors:  K D McDaniel
Journal:  Clin Neuropharmacol       Date:  1986       Impact factor: 1.592

4.  Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors.

Authors:  E Marley; K M Wozniak
Journal:  Psychol Med       Date:  1983-11       Impact factor: 7.723

Review 5.  Monoamine oxidase inhibitors: a review.

Authors:  G D Tollefson
Journal:  J Clin Psychiatry       Date:  1983-08       Impact factor: 4.384

6.  Amitriptyline protects patients on MAOIs from tyramine reactions.

Authors:  N S Kline; M Pare; C Hallstrom; T B Cooper
Journal:  J Clin Psychopharmacol       Date:  1982-12       Impact factor: 3.153

7.  Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.

Authors:  M P Schoerlin; M Mayersohn; A Korn; H Eggers
Journal:  Clin Pharmacol Ther       Date:  1987-10       Impact factor: 6.875

8.  Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M P Schoerlin; M Mayersohn; B Hoevels; H Eggers; M Dellenbach; J P Pfefen
Journal:  Clin Pharmacol Ther       Date:  1991-01       Impact factor: 6.875

Review 9.  Review of cimetidine drug interactions.

Authors:  E M Sorkin; D L Darvey
Journal:  Drug Intell Clin Pharm       Date:  1983-02

Review 10.  [Pharmacokinetics and metabolism of reversible MAO-A inhibitors in the human].

Authors:  M P Schoerlin; T W Guentert
Journal:  Psychiatr Prax       Date:  1989-08
View more
  8 in total

1.  Moclobemide monotherapy vs. combined therapy with valproic acid or carbamazepine in depressive patients: a pharmacokinetic interaction study.

Authors:  Anita Rakic Ignjatovic; Branislava Miljkovic; Dejan Todorovic; Ivana Timotijevic; Milena Pokrajac
Journal:  Br J Clin Pharmacol       Date:  2008-12-05       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.

Authors:  M Mayersohn; T W Guentert
Journal:  Clin Pharmacokinet       Date:  1995-11       Impact factor: 6.447

3.  Moclobemide versus fluoxetine for a major depressive episode.

Authors:  C Reynaert; M Parent; J Mirel; P Janne; L Haazen
Journal:  Psychopharmacology (Berl)       Date:  1995-03       Impact factor: 4.530

Review 4.  Risk-benefit assessment of newer versus older monoamine oxidase (MAO) inhibitors.

Authors:  Y Lecrubier
Journal:  Drug Saf       Date:  1994-04       Impact factor: 5.606

Review 5.  Adverse effects of opioid agonists and agonist-antagonists in anaesthesia.

Authors:  T A Bowdle
Journal:  Drug Saf       Date:  1998-09       Impact factor: 5.606

Review 6.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Authors:  N P Nair; S K Ahmed; N M Kin
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

Review 7.  A risk-benefit assessment of moclobemide in the treatment of depressive disorders.

Authors:  T R Norman; G D Burrows
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

8.  Monoamine Oxidase Inhibitors (MAOIs) in Psychiatric Practice: How to Use them Safely and Effectively.

Authors:  Samuel R Chamberlain; David S Baldwin
Journal:  CNS Drugs       Date:  2021-07-09       Impact factor: 5.749

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.